ARS Pharmaceuticals Shares Plunge 23% After Neffy Insurance Coverage Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Stock Price Plunge: ARS Pharmaceuticals (SPRY) shares fell 23% in after-hours trading on Wednesday, primarily due to the failure of its neffy nasal spray to secure commercial insurance coverage, which undermined investor confidence.
- Lack of Insurance Coverage: The company stated that no new commercial formulary additions or coverage decisions were made for neffy in the July 1, 2026 cycle, presenting a significant barrier to its market promotion efforts.
- Financial Guidance Downgrade: ARS Pharmaceuticals lowered its FY 2026 cash-based operating expense guidance to approximately $248 million, reflecting reduced spending in the second half of the year and a disciplined investment approach, indicating caution in financial management.
- Future Cash Flow Path: Despite facing challenges, the company reaffirmed that the neffy base business supports a path to cash-flow breakeven in 2027, demonstrating confidence in its long-term profitability prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPRY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPRY
Wall Street analysts forecast SPRY stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.280
Low
30.00
Averages
32.50
High
35.00
Current: 10.280
Low
30.00
Averages
32.50
High
35.00
About SPRY
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ARS Pharmaceuticals Lowers 2026 Operating Expense Outlook
- Operating Expense Reduction: ARS Pharmaceuticals has lowered its expected operating expenses for 2026 to $248 million, reflecting enhanced cost controls aimed at improving financial health and laying the groundwork for future profitability.
- Commercial Coverage Setback: The company failed to secure any new major commercial insurance coverage during the latest cycle, resulting in a more than 23% drop in after-hours stock trading, which could affect patient affordability and limit market expansion.
- Growing Demand: Despite challenges with insurance coverage, management highlighted that demand for neffy continues to grow, with approximately 120,000 patients using the product in the U.S. at the end of Q1, indicating strong market interest in needle-free alternatives.
- Increased Medicaid Coverage: ARS secured additional Medicaid coverage, including in Florida, which, while representing a smaller market opportunity, will improve access for some patients and help the company maintain a competitive edge amidst broader commercial coverage challenges.
See More
ARS Pharmaceuticals Shares Plunge 23% After Neffy Insurance Coverage Failure
- Stock Price Plunge: ARS Pharmaceuticals (SPRY) shares fell 23% in after-hours trading on Wednesday, primarily due to the failure of its neffy nasal spray to secure commercial insurance coverage, which undermined investor confidence.
- Lack of Insurance Coverage: The company stated that no new commercial formulary additions or coverage decisions were made for neffy in the July 1, 2026 cycle, presenting a significant barrier to its market promotion efforts.
- Financial Guidance Downgrade: ARS Pharmaceuticals lowered its FY 2026 cash-based operating expense guidance to approximately $248 million, reflecting reduced spending in the second half of the year and a disciplined investment approach, indicating caution in financial management.
- Future Cash Flow Path: Despite facing challenges, the company reaffirmed that the neffy base business supports a path to cash-flow breakeven in 2027, demonstrating confidence in its long-term profitability prospects.
See More
ARS Pharmaceuticals Faces Insurance Coverage Setback
- Insurance Coverage Challenge: ARS Pharmaceuticals' shares plummeted over 24% in after-hours trading after failing to secure broader commercial insurance coverage for its needle-free treatment Neffy, which investors view as a significant hurdle to sales growth and product adoption.
- Merger Deal Impact: Passage Bio's stock fell over 15% after announcing an all-stock merger with Remix Therapeutics, which will focus on RNA-processing therapies, indicating that the merger news did not provide the expected boost to investor confidence.
- Reverse Stock Split Volatility: Boxlight's shares surged 37% during regular trading following a 1-for-6 reverse stock split, but subsequently dropped over 17% in after-hours trading as investors took profits after the rapid increase, highlighting the stock's sensitivity to trading activity.
- Year-to-Date Performance: Year-to-date, Passage Bio and Boxlight have seen their stocks decline by 50% and 52%, respectively, while ARS Pharmaceuticals has dropped 9%, illustrating the vulnerability of small-cap stocks amid market fluctuations.
See More
ARS Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: ARS Pharmaceuticals reported total revenue of $22.7 million in Q1 2026, with U.S. net product revenue for neffy at $17.5 million, reflecting a 300% year-over-year increase, indicating strong market demand and product acceptance.
- Improved Coverage: The company achieved approximately 90% commercial coverage by the end of Q1, with 57% of patients not requiring prior authorization, and anticipates that CVS Caremark's recent proposal will further expand this proportion, enhancing patient access to neffy.
- Sales Team Expansion: ARS Pharmaceuticals has expanded its sales force to 148 representatives and area managers, adding approximately 29,500 new neffy users in Q1, bringing the total to 120,000 users, demonstrating positive progress in market outreach.
- Cash Flow Management: Despite SG&A expenses reaching $72.2 million in Q1, the company maintains a cash reserve of $201 million, with expectations for significant revenue growth in the second half of 2026, supporting the goal of achieving cash flow breakeven by mid-2027.
See More
Healthcare Stocks Decline on Friday Afternoon
- Healthcare Index Decline: The NYSE Healthcare Index fell by 0.9% on Friday afternoon, reflecting growing concerns in the market regarding the healthcare sector, which could impact investor confidence and lead to capital outflows from this segment.
- Market Reaction: The overall decline in healthcare stocks may be linked to economic data or policy changes, prompting investors to monitor future market dynamics to assess the long-term implications for the healthcare industry.
- Investor Sentiment: As healthcare stocks decline, investors may reassess their portfolios, particularly in the context of increasing economic uncertainty, potentially leading to a shift of funds towards other sectors.
- Industry Outlook: Short-term volatility in the healthcare sector could affect companies' financing capabilities and R&D investments, thereby impacting future innovation and market competitiveness.
See More
ARS Pharmaceuticals Q1 Earnings Report Analysis
- Earnings Performance: ARS Pharmaceuticals reported a Q1 GAAP EPS of -$0.61, missing expectations by $0.08, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $22.68 million, a remarkable 184.6% year-over-year increase, surpassing market expectations by $0.56 million, reflecting strong demand for its products, particularly during the launch phase.
- Cash Flow Position: As of March 31, 2026, ARS Pharma had cash, cash equivalents, and short-term investments totaling $201 million, with 99.3 million shares outstanding, indicating that its cash reserves are sufficient to fund operations until cash-flow break-even, showcasing robust financial management.
- Market Outlook: Despite significant revenue growth, the lack of guidance for 2026 may limit ARS Pharmaceuticals' market performance, prompting investors to closely monitor its future strategic plans and product launches.
See More
ARS Pharmaceuticals Lowers 2026 Operating Expense Outlook
- Operating Expense Reduction: ARS Pharmaceuticals has lowered its expected operating expenses for 2026 to $248 million, reflecting enhanced cost controls aimed at improving financial health and laying the groundwork for future profitability.
- Commercial Coverage Setback: The company failed to secure any new major commercial insurance coverage during the latest cycle, resulting in a more than 23% drop in after-hours stock trading, which could affect patient affordability and limit market expansion.
- Growing Demand: Despite challenges with insurance coverage, management highlighted that demand for neffy continues to grow, with approximately 120,000 patients using the product in the U.S. at the end of Q1, indicating strong market interest in needle-free alternatives.
- Increased Medicaid Coverage: ARS secured additional Medicaid coverage, including in Florida, which, while representing a smaller market opportunity, will improve access for some patients and help the company maintain a competitive edge amidst broader commercial coverage challenges.
See More
ARS Pharmaceuticals Shares Plunge 23% After Neffy Insurance Coverage Failure
- Stock Price Plunge: ARS Pharmaceuticals (SPRY) shares fell 23% in after-hours trading on Wednesday, primarily due to the failure of its neffy nasal spray to secure commercial insurance coverage, which undermined investor confidence.
- Lack of Insurance Coverage: The company stated that no new commercial formulary additions or coverage decisions were made for neffy in the July 1, 2026 cycle, presenting a significant barrier to its market promotion efforts.
- Financial Guidance Downgrade: ARS Pharmaceuticals lowered its FY 2026 cash-based operating expense guidance to approximately $248 million, reflecting reduced spending in the second half of the year and a disciplined investment approach, indicating caution in financial management.
- Future Cash Flow Path: Despite facing challenges, the company reaffirmed that the neffy base business supports a path to cash-flow breakeven in 2027, demonstrating confidence in its long-term profitability prospects.
See More
ARS Pharmaceuticals Faces Insurance Coverage Setback
- Insurance Coverage Challenge: ARS Pharmaceuticals' shares plummeted over 24% in after-hours trading after failing to secure broader commercial insurance coverage for its needle-free treatment Neffy, which investors view as a significant hurdle to sales growth and product adoption.
- Merger Deal Impact: Passage Bio's stock fell over 15% after announcing an all-stock merger with Remix Therapeutics, which will focus on RNA-processing therapies, indicating that the merger news did not provide the expected boost to investor confidence.
- Reverse Stock Split Volatility: Boxlight's shares surged 37% during regular trading following a 1-for-6 reverse stock split, but subsequently dropped over 17% in after-hours trading as investors took profits after the rapid increase, highlighting the stock's sensitivity to trading activity.
- Year-to-Date Performance: Year-to-date, Passage Bio and Boxlight have seen their stocks decline by 50% and 52%, respectively, while ARS Pharmaceuticals has dropped 9%, illustrating the vulnerability of small-cap stocks amid market fluctuations.
See More
ARS Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: ARS Pharmaceuticals reported total revenue of $22.7 million in Q1 2026, with U.S. net product revenue for neffy at $17.5 million, reflecting a 300% year-over-year increase, indicating strong market demand and product acceptance.
- Improved Coverage: The company achieved approximately 90% commercial coverage by the end of Q1, with 57% of patients not requiring prior authorization, and anticipates that CVS Caremark's recent proposal will further expand this proportion, enhancing patient access to neffy.
- Sales Team Expansion: ARS Pharmaceuticals has expanded its sales force to 148 representatives and area managers, adding approximately 29,500 new neffy users in Q1, bringing the total to 120,000 users, demonstrating positive progress in market outreach.
- Cash Flow Management: Despite SG&A expenses reaching $72.2 million in Q1, the company maintains a cash reserve of $201 million, with expectations for significant revenue growth in the second half of 2026, supporting the goal of achieving cash flow breakeven by mid-2027.
See More
Healthcare Stocks Decline on Friday Afternoon
- Healthcare Index Decline: The NYSE Healthcare Index fell by 0.9% on Friday afternoon, reflecting growing concerns in the market regarding the healthcare sector, which could impact investor confidence and lead to capital outflows from this segment.
- Market Reaction: The overall decline in healthcare stocks may be linked to economic data or policy changes, prompting investors to monitor future market dynamics to assess the long-term implications for the healthcare industry.
- Investor Sentiment: As healthcare stocks decline, investors may reassess their portfolios, particularly in the context of increasing economic uncertainty, potentially leading to a shift of funds towards other sectors.
- Industry Outlook: Short-term volatility in the healthcare sector could affect companies' financing capabilities and R&D investments, thereby impacting future innovation and market competitiveness.
See More
ARS Pharmaceuticals Q1 Earnings Report Analysis
- Earnings Performance: ARS Pharmaceuticals reported a Q1 GAAP EPS of -$0.61, missing expectations by $0.08, indicating challenges in profitability that may affect investor confidence.
- Revenue Growth: The company achieved revenues of $22.68 million, a remarkable 184.6% year-over-year increase, surpassing market expectations by $0.56 million, reflecting strong demand for its products, particularly during the launch phase.
- Cash Flow Position: As of March 31, 2026, ARS Pharma had cash, cash equivalents, and short-term investments totaling $201 million, with 99.3 million shares outstanding, indicating that its cash reserves are sufficient to fund operations until cash-flow break-even, showcasing robust financial management.
- Market Outlook: Despite significant revenue growth, the lack of guidance for 2026 may limit ARS Pharmaceuticals' market performance, prompting investors to closely monitor its future strategic plans and product launches.
See More
